Independent research firm IV Research analyzed on the 14th that SCL Science, a KOSDAQ-listed company, is expanding beyond its existing healthcare business into an artificial intelligence (AI) and data-based drug development platform and cancer vaccines. It did not provide an investment opinion or a target price.
IV Research said, "SCL Science is accelerating business diversification by expanding its hemostatic agent-centered revenue structure into digital healthcare and the bio logistics institutional sector." It also said, "In the hemostatic agent institutional sector, the company is expanding its market push with the 'InnoSeal' series based on proprietary technology, while in the digital platform institutional sector it is detailing a revenue model based on medical data linkage and patient experience."
It also noted that the bio logistics institutional sector is growing based on the network and other assets held by SCL Group. IV Research said, "This is a strategic move to expand the value chain by leveraging the existing infrastructure of a diagnostics-centered group and shifting to digital-based services."
SCL Science recently acquired cancer vaccine developer PentaMedix and set cancer vaccine development based on AI platform technology as a next-generation growth pillar. The plan is to combine SCL Group's medical data assets with AI technology to expand into precision medicine and immunotherapy.
IV Research explained, "A cancer vaccine is a treatment strategy that selects mutation-derived antigens (neoantigens) arising from a patient's own tumor, retrains the immune system, induces antigen-specific T-cell responses, and aims to target and eliminate tumors while suppressing recurrence."
It added, "SCL Science, through a data- and AI-centered precision medicine entry strategy, will supplement the technological paradigm of Moderna-BioNTech and, in the long term, form an intelligent competitive landscape that raises clinical success rates and improves the predictability of patient responses."